CN108514114A - Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory - Google Patents
Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory Download PDFInfo
- Publication number
- CN108514114A CN108514114A CN201810256191.6A CN201810256191A CN108514114A CN 108514114 A CN108514114 A CN 108514114A CN 201810256191 A CN201810256191 A CN 201810256191A CN 108514114 A CN108514114 A CN 108514114A
- Authority
- CN
- China
- Prior art keywords
- physical fatigue
- composition
- parts
- relieving physical
- nutrient theory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 13
- 240000007817 Olea europaea Species 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000003248 hydroxytyrosol Nutrition 0.000 claims description 6
- 229940095066 hydroxytyrosol Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- -1 patch Substances 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 238000002137 ultrasound extraction Methods 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 abstract description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract description 6
- 229960003080 taurine Drugs 0.000 abstract description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical group OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 abstract description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 abstract description 3
- 229960003966 nicotinamide Drugs 0.000 abstract description 3
- 235000005152 nicotinamide Nutrition 0.000 abstract description 3
- 239000011570 nicotinamide Substances 0.000 abstract description 3
- 229940055726 pantothenic acid Drugs 0.000 abstract description 3
- 235000019161 pantothenic acid Nutrition 0.000 abstract description 3
- 239000011713 pantothenic acid Substances 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000002552 dosage form Substances 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 37
- 241000699666 Mus <mouse, genus> Species 0.000 description 33
- 239000013642 negative control Substances 0.000 description 30
- 230000009182 swimming Effects 0.000 description 26
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 229920002527 Glycogen Polymers 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 239000004202 carbamide Substances 0.000 description 11
- 229940096919 glycogen Drugs 0.000 description 11
- 102100026189 Beta-galactosidase Human genes 0.000 description 10
- 108010059881 Lactase Proteins 0.000 description 10
- 108010005774 beta-Galactosidase Proteins 0.000 description 10
- 230000002440 hepatic effect Effects 0.000 description 10
- 229940116108 lactase Drugs 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 235000011576 oleuropein Nutrition 0.000 description 2
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101000855583 Homo sapiens Cysteine sulfinic acid decarboxylase Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to Food and hygienical food technical field, particularly relate to, based on the composition for relieving physical fatigue and application thereof of chondriosome nutrient theory, count, be made of following raw material in parts by weight：11 parts 15 parts of olive extract, 7.5 parts 12 parts of L-carnitine-L-tartrate, 0.8 part 1.2 parts of taurine, 5 parts 7.5 parts of niacinamide, 3.5 parts of Riboflavin Tetrabutyrate part, 1.5 parts 3 parts of pantothenic acid.Composition for relieving physical fatigue provided by the invention based on chondriosome nutrient theory reaches and alleviates physical fatigue effect, improves the working efficiency and quality of life of suitable population, and a variety of dosage forms can also be made and use；The composition has no toxic side effect, edible safety, definite functions, significant effect, is a kind of ideal composition for relieving physical fatigue.
Description
Technical field
The present invention relates to Food and hygienical food technical field, particularly relate to based on the slow of chondriosome nutrient theory
Composition of physical fatigue and application thereof.
Background technology
Fatigue refers to by the regular hour and reaching certain degree and the decline of mobility all occur, is shown as tired
Tired or DOMS or general weakness.The main physiology essence of fatigue is due to muscle activity and to the shadow of energetic supersession function
It rings.Fatigue can be divided into physical fatigue and mental fatigue.Physical fatigue, that is, exercise induced fatigue refers to by the body caused by body movement
Physiological function cannot be maintained on normal level or cannot maintain its original exercise intensity, and show under body movement ability
The phenomenon that drop.Mental fatigue refers to the fatigue that mental labour generates under certain condition, is mainly shown as and is weary of, mood agitation, remembers
Recall power decline, thought slowness, delay of response.The elimination that antifatigue effect seeks to the generation of delay fatigue and accelerates fatigue.
But health care product used for relieving physical fatigue type at present on the market is various, and function and effect are irregular.
Invention content
The present invention is intended to provide the composition for relieving physical fatigue that a kind of effect is good.
In order to solve the above technical problems, the technical scheme is that：
It based on the composition for relieving physical fatigue of chondriosome nutrient theory, counts in parts by weight, by following raw material system
At：
Wherein, hydroxytyrosol mass content is not less than 10% in the olive extract, the l-cn winestone
L-cn mass content is not less than 70% in hydrochlorate.
Preferably, it counts, is made of following raw material in parts by weight：
Further, the olive extract is the extract of olive water or organic solvent miscible with water；Described
Organic solvent miscible with water is any one in methanol, ethyl alcohol, acetone.
Further, the extracting method of olive extract be decoct extraction, refluxing extraction, soak extraction, ultrasonic extraction and
Any one or a few in seepage pressure effects.
Preferably, after raw material mixing, pharmaceutically acceptable auxiliary material is added, clinically-acceptable preparation is made；
The preparation includes tablet, pill, sustained release agent, effervescent agent, capsule, patch, extract, spray or drops.
The purposes of the composition for relieving physical fatigue, to be used to prepare the drug or health products of alleviating physical fatigue.
Hydroxytyrosol be it is a kind of it is natural there is fat-soluble, water-soluble and bioactivity polyphenol compound, it leads
If being present in each position of olive in the form of carboxylate oleuropein, oleuropein can obtain free after hydrolysis
Hydroxytyrosol.Hydroxytyrosol presents a large amount of beneficial characteristics, such as cancer chemoprevention, antiatherosclerosis, inhibition DNA
Oxidative damage, protection dermal photodamage and anti-inflammatory isoreactivity.
L-cn (L-carnitine) is a kind of amino acid promoting adipose conversion as energy, and red meat is left
The main source for revolving carnitine, has no toxic and side effect to human body.Different types of diet is containing 5-100 milligrams of left-handed meat
Alkali, but common people can only take in 50 milligrams from diet daily, and vegetarian's intake is less.The main Physiological Function of l-cn is
Promote adipose conversion at energy, take l-cn can while reducing body fat, losing weight, do not reduce moisture and
Muscle regarded as most safe fat-reducing nutrient complementary goods without side-effects in 2003 by International Obesity health tissues.L-cn
Tartrate is the stable form of l-cn, effect and effect and l-cn it is essentially identical.
Taurine (Taurine) is a kind of non-protein amino acid of sulfur-bearing, exists in vivo with free state, is not involved in body
The biosynthesis of interior albumen.Although taurine is not involved in protein synthesis, but it is close with the metabolism of cystine, cysteine
It is related.Cysteine sulfurous acid carboxylic acid (CSAD) activity of human body synthesizing taurine is relatively low, relies primarily on the ox in intake food
Sulfonic acid meets body needs.
Niacinamide is a kind of water soluble vitamin, belongs to B family vitamin, be cozymase (nicotinamide adenine dinucleotide,
NAD) and the constituent of codehydrogenase Ⅱ (nicotinamide-adenine dinucleotide phosphate, NADP), both coenzyme structures in human body
In nicotinoyl amine moiety there is reversible plus hydrogen and dehydrogenation characteristic, played in biological oxidation and pass hydrogen effect, tissue can be promoted to exhale
Suction, biological oxidation process and metabolism, to maintaining the integrality of normal structure especially skin, alimentary canal and nervous system to have
It is significant.
Riboflavin is water soluble vitamin, is easy digestion and absorbs, and discharged amount is with internal needs and may be with
The loss degree of protein and increased and decreased；It will not be accumulated in vivo, so to be supplemented often with food or nutritional supplement.
It is widely present in yeast, liver, kidney, egg, milk, soybean etc..
Pantothenic acid tool manufacture antibody function, also plays an important role in terms of safeguarding hair, skin and blood health.It is general
Effect is the metabolism participated in the manufacture of energy i (in vivo), and can control fat.It is nutriment necessary to brain and nerve.
Contribute to the secretion of internal compressive resistance hormone (steroids).It can keep the health of skin and hair.The formation of cell is helped,
Maintain the development of normal development and central nervous system；For maintaining adrenal normal function extremely important；It is fat and sugar
Class is transformed into indispensable substance when energy；The essential of p-aminobenzoic acid and choline is utilized in the synthesis of antibody, human body
Matter.
Using above-mentioned technical proposal, the present invention includes at least following advantageous effect：It is provided by the invention to be sought based on mitochondria
Support the theoretical composition for relieving physical fatigue of element, reach and alleviate physical fatigue effect, improve suitable population working efficiency and
Quality of life can also be made a variety of dosage forms and use；The composition has no toxic side effect, edible safety, definite functions, and effect is aobvious
It writes, is a kind of ideal composition for relieving physical fatigue.
Specific implementation mode
The technical solution in the present invention is clearly and completely described below in conjunction with specific embodiment, it is clear that retouched
The embodiment stated is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, originally
The every other embodiment that field those of ordinary skill is obtained without making creative work, belongs to the present invention
The range of protection.
Embodiment 1
It based on the composition for relieving physical fatigue of chondriosome nutrient theory, counts in parts by weight, by following raw material system
At：
Wherein, hydroxytyrosol mass content is not less than 10% in the olive extract, the l-cn winestone
L-cn mass content is not less than 70% in hydrochlorate.
Weigh taurine, olive extract, left acylcarnitine tartrate, niacinamide, riboflavin, pantothenic acid, starch, stearic acid
Softwood, the sieve granulation of 16 mesh, 55~60 DEG C of dryings, 14 mesh sieves, No. 0 capsule of loading, throwing is made with 80% ethyl alcohol in magnesium, mixing
Light, packaging are examined to get capsule for alleviating physical fatigue.
Embodiment 2
It is distinguished as with embodiment 1, counts in parts by weight, be made of following raw material：
Embodiment 3
It based on the composition for relieving physical fatigue of chondriosome nutrient theory, counts in parts by weight, by following raw material system
At：
Sample is carried out to 1 gained capsule of embodiment to test：
Check conclusion：
Sample " alleviates physical fatigue capsule " to show function of physical fatigue alleviation animal test results：
" alleviate physical fatigue capsule " is pressed into 30 times of human body recommended amounts, 20 times, 10 times of dose design, it is continuous to mouse
Gavage carries out each index determining after 30 days, as a result as follows：
1. each dosage group is compared with negative control group, each phase weight of mouse and weightening difference there are no significant (p>0 05)；
2 high dose groups can be obviously prolonged the mice burden swimming time, with the significant (p of negative control comparing difference<
0.05)；
3 high, middle dose group mice serum urea contents and the significant (p of negative control group comparing difference<0.05, p
<0.01)；
4 each dosage groups can increase the storage level of mouse hepatic glycogen, but with negative control group comparing difference without significantly
Property (1)>0.05)；
5 each dosage groups can reduce blood lactase acid area under the curve after mouse swimming, and high dose group and negative control group
Significant (the p of comparing difference<0,05)；
Foundation《Health food is examined and assessment technique specification》(version in 2003) can be determined that, " alleviating physical fatigue capsule "
With function of physical fatigue alleviation.
(note：Inspection result is only responsible for this submitted sample)
1. material and method
1.1 sample：Sample brown yellow granule and powder.Human body recommended amounts be 2 times a day, 3 tablets each time, every 0.35g.
Weight of being grown up is calculated by 60kg, and it is 0.035g/kg.bw to convert into dosage.Sample is prepared with distillation water as solvent.
1.2 experimental animal：There is provided male mice in kunming by Xi'an Jiaotong University Medical College's Experimental Animal Center, (quality is closed
Lattice card number：
61001700000932) 200, weight 18-22g, the correct mouse of swimming position 160 is selected to be served only for testing.
Production licence number：SCXK (Shan) 2012-003, SPF grade.Animal feed bedding and padding are same as above.Experimental animal room is barrier system, is made
It is SYXK (Shan) 2,012 1 006,20 1 25 DEG C of temperature, relative humidity 45%65% with credit number.
1.3 dosage are selected and are prepared：Because of the daily recommended amounts 2.1g/60kg.bw (0.035g/kg.bw) of human body, therefore dosage is set
Meter：Experiment set tri- dosage groups of 1.05g, 0.70g, 0.35g/kg.bw (be respectively equivalent to human body recommend dosage 30,20,10 times),
It is another to set negative (distilled water) control group.Sample preparation：1.05g, 0.70g, 0.35g sample are weighed, respectively plus distilled water is to 20mL,
It is uniformly mixed.
1.4 instruments and reagent：
1.4.1 key instrument, article：Swimming trunk, JD5002 electronic balances, stopwatch, sheet lead, UV-7504 UV, visible lights
Spectrophotometer, Shenzhen step auspicious BS-420 automatic clinical chemistry analyzers, 10mL tool plug test tubes, thermometer, constant water bath box, centrifugation
Machine, vortex oscillator, surgical instrument, micro sample adding appliance, suction pipe, graduated centrifuge tube etc..
1.4.2 reagent：Kit (production of Sai Hao Science and Technology Ltd.s is built up in Nanjing), (Shenzhen steps auspicious biochemical analysis reagent
Biologic medical electronics limited liability company produces) etc..
1.5 test method：Correct set hero mouse 160 will be selected after swimming in advance, be divided into four test groups, it is each to test
40 mouse of group are simultaneously randomly divided into 4 groups, and each test group is all provided with three dosage groups and negative control group.Experimental animal number is 10
Only.One group of Loaned swimming test is tested, two groups of serum urea experiments are tested, tests three groups of hepatic glycogen experiments, tests four groups of blood breasts
Acid experiment.Primary by the daily orally administration corresponding dosage sample of above-mentioned dosage, gavage volume is 20mL/kg.bw.Negative control group
Give equal capacity distilled water, continuous gavage 30 days.Then the measurement of indices is carried out respectively, and method is as follows：
1.5.1 mice burden swimming test：After last gives sample after 30min, mouse is placed in swimming trunk went swimming,
Depth of water 35cm, 25 DEG C of water temperature, the sheet lead of 5% weight of rat-tail root load.Record each group mouse from swim to death when
Between, as the mice burden swimming time, the carry out variance analysis compared with negative control group of each dosage group result.Dead criterion
For：Mouse is sink to swimming trunk bottom and stops mouth breathing.If dosage group swimming time is considerably longer than negative control group swimming time,
And significant (the P of difference<0.05) it, can determine that the sample plays the role of extending the mice burden swimming time.
1.5.2 mice serum urea measures：After last gives sample 30min, do not bear a heavy burden in the water that temperature is 30 DEG C
Swimming 90 minutes, after movement rest 60 and.Pull out eyeball blood sampling 0.5ml, 2000r/min centrifuge after 15min, separation serum with it is complete from
Automatic Biochemical Analyzer carries out serum urea measurement, the carry out variance analysis compared with negative control group of each dosage group result.If dosage
Group serum urea content is significantly lower than negative control group, and the significant (p of difference<0.05) it is tired, to can determine that the sample is reduced
The effect that labor mouse urea generates.
1.5.3 mouse hepatic glycogen measures：Sample 30 is given in last.After put to death animal, liver is taken out in dissection, by kit
It is required that carrying out hepatic glycogen measurement, the carry out variance analysis compared with negative control group of each dosage group result.Hepatic glycogen is measured using south
The kit that the production of Sai Hao Science and Technology Ltd.s is built up in capital is measured.If dosage group hepatic glycogen content is apparently higher than negative control
Group, and significant difference (p<0.05).It can determine that the sample has and promote the effect of mouse liver glycogen reserves.
1.5.4 mouse blood lactase acid measures：After last gives sample 30min, mouse not swimming with a load attached to the body in 30 DEG C of water
10min, before swimming, swimming after and swimming after rest 20min, respectively three times blood sampling 20ul (endocanthion blood sampling) measurement blood lactase acid contain
Amount, using three time point blood lactase acid area under the curve as index, by each dosage group result compared with negative control group carry out variance
Analysis.Blood lactase acid measures the kit for using Nanjing to build up the production of Sai Hao Science and Technology Ltd.s and is measured.If dosage group blood breast
Sour area under the curve is significantly less than negative control group, and the significant (p of difference<0.05) it, can determine that the sample has reduction mouse
The effect of blood lactase acid area under the curve after swimming.
1.6 test datas count：Homogeneity test of variance is carried out to each experiment initial data with spss softwares, meets " variance
Mean compares two-by-two between the data information one-way analysis of variance method required together " and multiple test groups and a control group
Method carries out statistical disposition；Variable conversion appropriate is carried out to the data information of Non-Gaussian Distribution or heterogeneity of variance, waits meeting " just
State variance is neat " after requiring, statistical disposition to be carried out with the data of conversion gained.
1.7 result judgement：Loaned swimming test result is positive, and three blood lactase acid, serum urea, hepatic glycogen biochemical indicators
In appoint binomial index positive, you can judge that the sample has the function of function of physical fatigue alleviation.
2 results
2.1 mice burden swimming test
By table 1 as it can be seen that each phase weight of each dosage group mouse and weightening are compared with negative control group, difference there are no significant (p
＞ 0.05).
Table 1 thinks influence of the board alleviation physical fatigue capsule in source to mouse weight
As can be seen from Table 2, each dosage group mouse average swim time extends compared with negative control group swimming time, and high dose
Group and negative control group comparing difference are significant (p ＜ 0,05).
Table 2 thinks source board alleviation physical fatigue capsule mice burden swimming test result
Note：Compared with solvent control group, * indicates P ＜ 0.05.
2.2 mice serum urea measure
By table 3 as it can be seen that each phase weight of each dosage group mouse and weightening are compared with negative control, without significant difference (p ＞
0.05)
Table 3 thinks influence of the board alleviation physical fatigue capsule in source to mouse weight
By table 4 as it can be seen that height, middle dose group mice serum urea and significant (the p ＜ of negative control group comparing difference
0.05, P ＜ 0.01).
Table 4 thinks influence of the board alleviation physical fatigue capsule in source to mice serum urea content
Note：Compared with solvent control group, * indicates that P ＜ 0.05, * * indicate P ＜ 0.01.
23 mouse hepatic glycogen measure
By table 5 as it can be seen that each phase weight of each dosage group mouse and weightening are compared with negative control group, difference there are no significant (p
＞ 0,05).
Table 5 thinks influence of the board alleviation physical fatigue capsule in source to mouse weight
By table 6 as it can be seen that each dosage group can increase the storage level of mouse hepatic glycogen, but it is equal with negative control group comparing difference
Without conspicuousness (P ＞ 0.05).
2.4 mouse blood lactase acids measure
By table 7 as it can be seen that each phase weight of each dosage group mouse and weightening are compared with negative control group, difference there are no significant (p
＞ 0.05).
Table 7 thinks influence of the board alleviation physical fatigue capsule in source to mouse weight
By table 8 as it can be seen that three time point blood lactase acid area under the curve of each dosage group mouse are respectively less than negative control group, and it is high
Dosage group and negative control group comparing difference are significant (p ＜ 0.05).
Table 8 thinks source board and alleviates physical fatigue capsule to swim to mouse the influence of forward and backward Serum lactic acid content
Note：Compared with solvent control group, * indicates P ＜ 0.05
3. brief summary
" alleviate physical fatigue capsule " is pressed into 30 times of human body recommended amounts, 20 times, 10 times of dose design, it is continuous to mouse
Gavage carries out each index determining after 30 days, as a result as follows：
3.1 each dosage groups are compared with negative control group, each phase weight of mouse and weightening difference there are no significant (p>0.05)；
3.2 high dose groups can be obviously prolonged the mice burden swimming time, with the significant (p of negative control comparing difference<
0.05)；
3.3 high, middle dose group mice serum urea contents and the significant (p of negative control group comparing difference<0.05, p
<0.01)；
3.4 each dosage groups can increase the storage level of mouse hepatic glycogen, but with negative control group comparing difference without significantly
Property (p>0.05)；
3.5 each dosage groups can reduce blood lactase acid area under the curve after mouse swimming, and high dose group and negative control group
Significant (the p of comparing difference<0.05)；
Foundation《Health food is examined and assessment technique specification》(version in 2003) can be determined that, " it is tired think source board alleviation muscle power
Labor glue capsule " has function of physical fatigue alleviation.
The foregoing description of the disclosed embodiments enables those skilled in the art to implement or use the present invention.
Various modifications to these embodiments will be apparent to those skilled in the art, as defined herein
General Principle can be realized in other embodiments without departing from the spirit or scope of the present invention.Therefore, of the invention
It is not intended to be limited to the embodiments shown herein, and is to fit to and the principles and novel features disclosed herein phase one
The widest range caused.
Claims (6)
1. the composition for relieving physical fatigue based on chondriosome nutrient theory, which is characterized in that count in parts by weight, by with
Lower raw material is made：
Wherein, hydroxytyrosol mass content is not less than 10% in the olive extract, the L-carnitine-L-tartrate
Middle l-cn mass content is not less than 70%.
2. the composition for relieving physical fatigue according to claim 1 based on chondriosome nutrient theory, feature exist
In counting, be made of following raw material in parts by weight：
3. the composition for relieving physical fatigue according to claim 1 based on chondriosome nutrient theory, feature exist
In the olive extract is the extract of olive water or organic solvent miscible with water；It is described miscible with water organic
Solvent is any one in methanol, ethyl alcohol, acetone.
4. the composition for relieving physical fatigue according to claim 3 based on chondriosome nutrient theory, feature exist
In the extracting method of olive extract is to decoct appointing in extraction, refluxing extraction, soak extraction, ultrasonic extraction and seepage pressure effects
Meaning is one or more of.
5. the composition for relieving physical fatigue according to claim 1 based on chondriosome nutrient theory, feature exist
After the mixing of, the raw material, pharmaceutically acceptable auxiliary material is added, clinically-acceptable preparation is made；The preparation packet
Include tablet, pill, sustained release agent, effervescent agent, capsule, patch, extract, spray or drops.
6. according to composition for relieving physical fatigue of claim 1 to 5 any one of them based on chondriosome nutrient theory
Purposes, it is characterised in that：It is used to prepare the drug or health products for alleviating physical fatigue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810256191.6A CN108514114A (en) | 2018-03-27 | 2018-03-27 | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810256191.6A CN108514114A (en) | 2018-03-27 | 2018-03-27 | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108514114A true CN108514114A (en) | 2018-09-11 |
Family
ID=63433023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810256191.6A Pending CN108514114A (en) | 2018-03-27 | 2018-03-27 | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108514114A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111357992A (en) * | 2020-03-27 | 2020-07-03 | 山东新稀宝股份有限公司 | Composition capable of relieving physical fatigue and application thereof |
| CN113439809A (en) * | 2021-05-24 | 2021-09-28 | 哈尔滨工业大学 | Liquid preparation with antioxidant and anti-fatigue functions and preparation method thereof |
| WO2024099884A1 (en) * | 2022-11-09 | 2024-05-16 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of oleuropein and taurine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293572A1 (en) * | 2004-05-11 | 2007-12-20 | Hideyuki Kishida | Anti-Fatigue Composition |
| CN101522182A (en) * | 2006-10-05 | 2009-09-02 | 帝斯曼知识产权资产管理有限公司 | Olive juice extracts for promoting muscle health |
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103316032A (en) * | 2013-05-24 | 2013-09-25 | 凌霄 | A hydroxytyrosol composition and applications thereof |
-
2018
- 2018-03-27 CN CN201810256191.6A patent/CN108514114A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070293572A1 (en) * | 2004-05-11 | 2007-12-20 | Hideyuki Kishida | Anti-Fatigue Composition |
| CN101522182A (en) * | 2006-10-05 | 2009-09-02 | 帝斯曼知识产权资产管理有限公司 | Olive juice extracts for promoting muscle health |
| CN103110114A (en) * | 2011-11-16 | 2013-05-22 | 北京康比特体育科技股份有限公司 | Beta-alanine-containing composition for endurance increase, and preparation thereof |
| CN103316032A (en) * | 2013-05-24 | 2013-09-25 | 凌霄 | A hydroxytyrosol composition and applications thereof |
Non-Patent Citations (1)
| Title |
|---|
| 赵艳霞等: "油橄榄叶羟基酪醇提取工艺优化及抗氧化研究", 《食品工业》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111357992A (en) * | 2020-03-27 | 2020-07-03 | 山东新稀宝股份有限公司 | Composition capable of relieving physical fatigue and application thereof |
| CN113439809A (en) * | 2021-05-24 | 2021-09-28 | 哈尔滨工业大学 | Liquid preparation with antioxidant and anti-fatigue functions and preparation method thereof |
| WO2024099884A1 (en) * | 2022-11-09 | 2024-05-16 | Société des Produits Nestlé S.A. | Compositions and methods using a combination of oleuropein and taurine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885309B (en) | Chloasma removing healthcare food composite and preparation method thereof | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN103829140A (en) | Cereal powder with functions of losing weight and reducing blood sugar | |
| CN108514114A (en) | Composition for relieving physical fatigue and purposes based on chondriosome nutrient theory | |
| WO2023005265A1 (en) | Application of nucleotide mixture in preparation of formulations for preventing or alleviating senile sarcopaenia | |
| CN104397538A (en) | Health-care diet food | |
| CN101637491A (en) | Health-care food having functions of assisting antidiabetics and assisting antiatheroscloresis preparation method thereof | |
| CN105555286A (en) | Activated soy pod fiber | |
| CN111528470A (en) | Preparation method of calcium roxburgh rose complex, product and application thereof | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN106509887A (en) | Fatigue preventing health-care composition and a preparation method thereof | |
| CN108065286A (en) | A kind of chewable tablets containing acerola concentrate powder, VC and taurine and preparation method thereof | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN106942578A (en) | A kind of natural meals for controlling purine intake and promoting uric acid excretion | |
| CN105725187A (en) | Blood sugar reducing composition and application in preparation of foods and health-care foods | |
| CN101356975A (en) | Health food capable of increasing human immunity and promoting intelligence and strengthening brain and preparation method thereof | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| CN101618087B (en) | Health-care food with function of improving climacteric | |
| CN106692532A (en) | Traditional Chinese medicine composition used for burning fat and losing weight as well as patch and weight losing package thereof | |
| CN102885311A (en) | Composite health food composition for alleviating physical fatigue and preparation method thereof | |
| CN105963327A (en) | Vitamin K2 composition for prevention and treatment of liver function impairment | |
| CN105639620A (en) | Health food composition for increasing bone mineral density, and preparation method thereof | |
| CN102596214A (en) | Composition for alleviating fatty liver | |
| CN101804083B (en) | Application of pollen pini and extract thereof in treating inflammatory bowel disease and method for preparing extract | |
| CN104256576B (en) | Functional food capable of regulating blood pressure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180911 |
|
| RJ01 | Rejection of invention patent application after publication |